Safety, tolerability, and pharmacokinetics of single and multiple topical ophthalmic administration of imatinib mesylate in healthy subjects

For the long‐term efficacy of dry eye disease treatment, relieving underlying inflammation is necessary. Imatinib mesylate is a novel ophthalmic formulation of imatinib mesylate, which is expected to alleviate inflammation by inhibiting the discoidin domain receptor 1 activity. This study aims to ev...

Descripción completa

Detalles Bibliográficos
Autores principales: Na, Joo Young, Huh, Ki Young, Yu, Kyung‐Sang, Hyon, Joon Young, Koo, Hye Cheong, Lee, Jong Ho, You, Ji Chang, Chung, Jae‐Yong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9099133/
https://www.ncbi.nlm.nih.gov/pubmed/35133064
http://dx.doi.org/10.1111/cts.13226

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9099133/
https://www.ncbi.nlm.nih.gov/pubmed/35133064
http://dx.doi.org/10.1111/cts.13226

Ejemplares similares